SREBF2 and metabolic dysfunction-associated steatotic liver disease: Stimulated lipogenesis mediated by overexpressing SREBP1 and SREBP2 and their target genes (i.e., FAS/ACC-1 and HMGCoAR) with a concomitant reduction in β-oxidation due to suppression of PPARα/CPT1 axis mediated NAFLD in diabetic animals (Oliveira et al.